Paper23944843
Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats.
Cui JJ and 12 others. J Med Chem, 2013. Cited by 28 papers, by iCite.
Cite this record
ConductScience Library. Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats. Papers, record 23944843. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23944843
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cardiomyopathies | Major topic |
| Phosphodiesterase Inhibitors | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Quinolines | Major topic |
| Receptor Protein-Tyrosine Kinases | Major topic |
| Animals | |
| Female | |
| Humans | |
| Mice | |
| Mice, Nude | |
| Models, Molecular | |
| Rats |
Source PubMed
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41368778 | Design and Development of [1,2,4]Triazolo[4,3-b][1,2,4]triazines as Potential Anticancer Agents with Genotoxicity and Apoptotic Activity. | Med Chem | 2025 | https://conductscience.org/library/papers/41368778 | PubMed |
| 40678487 | Scaffold and SAR studies on c-MET inhibitors using machine learning approaches. | J Pharm Anal | 2025 | https://conductscience.org/library/papers/40678487 | PubMed |
| 40536894 | Tyrosine-Mediated Static and Dynamic Quenching of a Receptor Tyrosine Kinase Biosensor Reveals Inhibitor Binding Modes and Kinase Conformations. | ACS Chem Biol | 2025 | https://conductscience.org/library/papers/40536894 | PubMed |
| 40182503 | Fluorescence based live cell imaging identifies exon 14 skipped hepatocyte growth factor receptor (MET) degraders. | RSC Adv | 2025 | https://conductscience.org/library/papers/40182503 | PubMed |
| 39720556 | Recent advances in the treatment of non-small cell lung cancer with MET inhibitors. | Front Chem | 2024 | https://conductscience.org/library/papers/39720556 | PubMed |
| 39291032 | Design and Synthesis of c-Met and HDAC Dual Inhibitors for the Treatment of Breast Cancer. | ACS Med Chem Lett | 2024 | https://conductscience.org/library/papers/39291032 | PubMed |
| 35897857 | Syntheses and Applications of 1,2,3-Triazole-Fused Pyrazines and Pyridazines. | Molecules | 2022 | https://conductscience.org/library/papers/35897857 | PubMed |
| 34247323 | Type II c-Met inhibitors: molecular insight into crucial interactions for effective inhibition. | Mol Divers | 2022 | https://conductscience.org/library/papers/34247323 | PubMed |
| 32775889 | Dual Targeting of VEGFR2 and C-Met Kinases via the Design and Synthesis of Substituted 3-(Triazolo-thiadiazin-3-yl)indolin-2-one Derivatives as Angiogenesis Inhibitors. | ACS Omega | 2020 | https://conductscience.org/library/papers/32775889 | PubMed |
| 32549194 | Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32549194 | PubMed |
| 32117981 | The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma. | Front Cell Dev Biol | 2020 | https://conductscience.org/library/papers/32117981 | PubMed |
| 31030415 | In Vitro Metabolism by Aldehyde Oxidase Leads to Poor Pharmacokinetic Profile in Rats for c-Met Inhibitor MET401. | Eur J Drug Metab Pharmacokinet | 2019 | https://conductscience.org/library/papers/31030415 | PubMed |
| 28587113 | The Therapeutic Targeting of HGF/c-Met Signaling in Hepatocellular Carcinoma: Alternative Approaches. | Cancers (Basel) | 2017 | https://conductscience.org/library/papers/28587113 | PubMed |
| 28404966 | A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer. | Oncotarget | 2017 | https://conductscience.org/library/papers/28404966 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23944843
GET https://conductscience.org/api/papers/v1/23944843/authors